Archives
GnRH Antagonists Modified with 3-(2-Methoxy-5-pyridyl)-alani
2026-05-01
Evaluating Stereochemical Modifications of GnRH Antagonists: Implications for Peptide Therapeutic Development
Study Background and Research Question
Gonadotropin-releasing hormone (GnRH) is a decapeptide hormone central to regulating reproductive function via pituitary gonadotropin release. Peptide-based GnRH antagonists have emerged as important therapeutic candidates for conditions such as hormone-dependent cancers and endometriosis, offering advantages over agonists by producing rapid suppression without an initial hormone surge (source: paper). A persistent challenge, however, is the development of antagonists that combine high potency, metabolic stability, and long-lasting in vivo effects. The reference study addresses whether introducing a specific unnatural amino acid, 3-(2-methoxy-5-pyridyl)-alanine (2-OMe-5Pal), at position 3 in degarelix can optimize these properties.Key Innovation from the Reference Study
The primary innovation lies in the stereoselective modification of degarelix—a clinically advanced GnRH antagonist—by replacing the conventional residue at position 3 with either D- or L-configured 2-OMe-5Pal. The two resulting diastereomers were separated and individually characterized to assess the influence of stereochemistry on receptor antagonism and duration of action. By leveraging unnatural amino acids, the authors probe the structure-activity relationship at a key pharmacophore position that is known to affect both potency and metabolic stability (source: paper).Methods and Experimental Design Insights
The research team synthesized both D- and L-2-OMe-5Pal analogs of degarelix using solid-phase peptide synthesis (SPPS) protocols, followed by purification with reverse-phase high-performance liquid chromatography (RP-HPLC). The absolute configuration at position 3 was verified through enzymatic digestion using proteinase K, exploiting the enzyme's stereospecificity. Analytical confirmation was performed by mass spectrometry (ESI-MS, MALDI-MS) and NMR. In vitro assays measured antagonism of the human GnRH receptor, reporting IC50 values for each analog. For in vivo assessment, the compounds were administered subcutaneously to castrated male rats, a standard model for evaluating the suppression of gonadotropin-driven physiology. The duration of action was compared to unmodified degarelix.Protocol Parameters
- assay | solid-phase peptide synthesis (SPPS) | Fmoc chemistry, RP-HPLC purification | applicable for synthesizing peptide analogs with unnatural residues | Ensures sequence fidelity and high yield for SAR studies | source: paper
- in vitro GnRH receptor antagonism | IC50 (D-2-OMe-5Pal: 5.22 nM; L-2-OMe-5Pal: 36.95 nM) | human recombinant receptor, cell-based | Quantifies potency of modified antagonists | Direct comparison of diastereomeric effects | source: paper
- in vivo duration of action | short-acting relative to parent degarelix | castrated male rat | Assesses pharmacodynamic persistence | Reveals the impact of modification on half-life | source: paper
- workflow recommendation | use high-purity reagents for peptide synthesis and receptor assays | broad applicability | Minimizes batch variability and enhances reproducibility in SAR studies | workflow_recommendation